User:Wilfred J. Poppinga/Notebook/cAMP compartmentalization/2010/02/18: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(20 intermediate revisions by the same user not shown)
Line 11: Line 11:
<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->
<!-- ##### DO NOT edit above this line unless you know what you are doing. ##### -->
==Summary==
==Summary==
* Short summary
To determine the amount of interleukin 8 (IL-8) produced by the airway smooth muscle cells (ASMC's) [http://en.wikipedia.org/wiki/ELISA ELISA] is performed using the PeliKine Compact™ human IL-8 ELISA kit. In this way the effect of PKA, EPAC and CSE on the inflammatory cytokine can be determined.
 
==Materials & Methods==
==Materials & Methods==
===Materials===
===Materials===
* Coating buffer
* Coating buffer
* IL-8 antibody
* IL-8 antibody Coating antibody
* 96-wells plate (MaxiSorb)
* 96-wells plate (MaxiSorb)
* [[PBS]]
* [[PBS]] 5%
* [http://en.wikipedia.org/wiki/Bovine_serum_albumin BSA]
* [http://en.wikipedia.org/wiki/Bovine_serum_albumin BSA] 5% (in PBS)
* [http://www.sanquin.pl/datasheet/m1918.pdf Pelikine Compact™ Human IL-8 ELISA kit]
* [http://www.sanquin.pl/datasheet/m1918.pdf Pelikine Compact™ Human IL-8 ELISA kit]
* Washing buffer
* Washing buffer (PBS + 0.005% TWEEN 20)
* IL-8 antibody
* IL-8 antibody
 
* Streptavidin conjugated to HRP
* Substrate buffer
** 1.5 sodiumacetate, resuspend in 80 mL ultrapure water
** pH 5.5
** up to 100 mL with ultrapure water
* TMB stock solution (light sensitive)
** 30 mg [http://en.wikipedia.org/wiki/3,3%E2%80%99,5,5%E2%80%99-Tetramethylbenzidine TMB]
** 5 mL [http://en.wikipedia.org/wiki/Dimethyl_sulfoxide DMSO]


===Method===
===Method===
Line 50: Line 56:
|-
|-
|A
|A
|100/100
|style="background:red"|100/100
|100/100
|style="background:red"|100/100
|100/100
|style="background:red"|100/100
|100/100
|style="background:red"|100/100
|100/100
|style="background:red"|100/100
|100/100
|style="background:red"|100/100
|-
|-
|B
|B
|150/50
|style="background:green"|150/50
|150/50
|style="background:green"|150/50
|150/50
|style="background:green"|150/50
|175/25
|style="background:blue; color:white" |175/25
|175/25
|style="background:blue; color:white" |175/25
|175/25
|style="background:blue; color:white" |175/25
|-
|-
|C
|C
|150/50
|style="background:green"|150/50
|150/50
|style="background:green"|150/50
|150/50
|style="background:green"|150/50
|175/25
|style="background:blue; color:white" |175/25
|175/25
|style="background:blue; color:white" |175/25
|175/25
|style="background:blue; color:white" |175/25
|-
|-
|D  
|D  
|150/50
|style="background:green"|150/50
|150/50
|style="background:green"|150/50
|150/50
|style="background:green"|150/50
|175/25
|style="background:blue; color:white" |175/25
|175/25
|style="background:blue; color:white" |175/25
|175/25  
|style="background:blue; color:white" |175/25  
|-
|-
|}
|}
Line 86: Line 92:
* Add 100 μL of diluted sample
* Add 100 μL of diluted sample
* Incubate ≥1h @ RT
* Incubate ≥1h @ RT
* Was 5x 200 μL Washing buffer
* Wash 5x 200 μL Washing buffer
* Remove buffer
* Remove buffer
** {{todo| prepare biotinylated antibody}}
** {{todo| prepare biotinylated antibody}}
* Add 100 μL Biotinylated antibody
* Add 100 μL Biotinylated antibody
* Incubate 1h @ RT
* Incubate 1h @ RT
* Remove antibody
* Wash 5x 200 μL Washing buffer
* Add 100 μL streptavidin conjugated to HRP
* Incubate 25 min. @ RT
* Remove liquid
* Wash 5x 200 μL Washing buffer
** {{todo| prepare TBM substrate}}
** 1.2 μL H<sub>2</sub>O<sub>2</sub> (30%)
** 400 μL TBM stock solution
** 24 mL substrate buffer
* Add 100 μL substrate
* Incubate 30 min. @ RT
* Stop reaction, add 100 μL stopping solution
** It will turn yellow
* Measure absorbance @ 450 nm
** Check duplo standard curve
** Check if values fall within standard curve (preferred)
<!--{| border="1"
<!--{| border="1"
|+'''96-wells plate'''
|+'''96-wells plate'''
Line 238: Line 261:
* Of the 96-wells plate well F1 contain a Polystyrene fragment
* Of the 96-wells plate well F1 contain a Polystyrene fragment
==Results==
==Results==
*{{todo| WHAT?}}
* Standard curves were accurate (R square 1>0.99)
* Negative controls showed hardly any IL-8 secretion into the medium (see figures below)
[[Image:AverageIL8secretionD918022010.JPG|500px]]<BR>
<b>Image 180220101: The average IL-8 secretion of donor 9 corrected for  [[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/17| cell viability]]. Error bars represent standard deviation. CTR: control, CSE: Cigarette smoke extract, 8-p: 8-pcpt-2'-o-me-camp, Bnz:6-Benz-cAMP.</b><BR>
[[Image:AverageIL8secretionD1218022010.JPG|500px]]<BR>
<b>Image 180220102: The average IL-8 secretion of donor 12 corrected for  [[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/17| cell viability]]. Error bars represent standard deviation. CTR: control, CSE: Cigarette smoke extract, 8-p: 8-pcpt-2'-o-me-camp, Bnz:6-Benz-cAMP.</b><BR>
* Donor 9 showed twice as low IL-8 concentrations (see figures


==Conclusion==
==Conclusion==
*{{done}} Ow..
*It appears that HT31P affects the cells viability negatively.  
==Related==
*When comparing the effect of CSE without (HT31P) and with (HT31) PKA/AKAP interaction inhibition, it seems that when AKAP/PKA association is inhibited it decreases CSE induced IL-8 release.
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/10| Splitting cells]]
** PKA/AKAP interaction is required for CSE induced IL-8 secretion.
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/12| Counting cells]]
* When inducing Epac no effect is seen when comparing the HT31 situation, however slight decrease of IL-8 production is seen when HT31P control situation receives Epac stimulation.  
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/15| Putting cells to S<sup>0</sup>]]
** When Epac can compete with PKA for the present cAMP it inhibits the increased IL-8 secretion.
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/16| Stimulation of cells]]
** Epac does not have an influence when PKA can not have its effect
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/17| Viability staining]]
* Increased PKA activity induces inhibition of IL-8 secretion even without AKAP association
** It might be that PKA is activated prior to AKAP association, removing its necessity
 
 
*<b>PKA/AKAP induces IL-8 secretion, however an excess of active PKA with/without AKAP association lowers IL-8 secretion</b>
** Ht31 does not prevent the activation of PKA, only its localization close to cAMP sources and PKA effectors
*<b> PKA is the more important effector of cAMP compared to Epac</b>


==Related entries==
===Run 1: Ht31/Ht31P D9/D12===
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/10|Splitting cells 10Feb2010]]
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/12|Counting cells 12Feb2010]]
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/15|Putting to S<sup>0</sup> 15Feb2010]]
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/16|Stimulating cells 16Feb2010]]
*[[User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/17|Ending stimulation & Viability 17Feb2010]]
==Attachment==
<html>
<a href="http://openwetware.org/wiki/Image:HTERT_Donor_12_ht31_160310.xls">
  <img src="http://openwetware.org/images/f/f8/Owwnotebook_icon.png" alt="" width="50" height="50">
</a>
</html> [[Media:HTERT_Donor_9_ht31_180210.xls| Excel hTERT D9]]
<br>
<html>
<a href="http://openwetware.org/wiki/Image:HTERT_Donor_12_ht31_160310.xls">
  <img src="http://openwetware.org/images/f/f8/Owwnotebook_icon.png" alt="" width="50" height="50">
</a>
</html> [[Media:HTERT_Donor_12_ht31_180210.xls| Excel hTERT D12]]


<!-- ##### DO NOT edit below this line unless you know what you are doing. ##### -->
<!-- ##### DO NOT edit below this line unless you know what you are doing. ##### -->

Revision as of 01:19, 26 March 2010

<html><style type="text/css"> .todo { color: red } .done { color: green} </style></html>

ELISA <html><img src="/images/9/94/Report.png" border="0" /></html> Main project page
<html><img src="/images/c/c3/Resultset_previous.png" border="0" /></html>Previous entry<html>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</html>Next entry<html><img src="/images/5/5c/Resultset_next.png" border="0" /></html>

Summary

To determine the amount of interleukin 8 (IL-8) produced by the airway smooth muscle cells (ASMC's) ELISA is performed using the PeliKine Compact™ human IL-8 ELISA kit. In this way the effect of PKA, EPAC and CSE on the inflammatory cytokine can be determined.

Materials & Methods

Materials

  • Coating buffer
  • IL-8 antibody Coating antibody
  • 96-wells plate (MaxiSorb)
  • PBS 5%
  • BSA 5% (in PBS)
  • Pelikine Compact™ Human IL-8 ELISA kit
  • Washing buffer (PBS + 0.005% TWEEN 20)
  • IL-8 antibody
  • Streptavidin conjugated to HRP
  • Substrate buffer
    • 1.5 sodiumacetate, resuspend in 80 mL ultrapure water
    • pH 5.5
    • up to 100 mL with ultrapure water
  • TMB stock solution (light sensitive)

Method

Coating of plate

  • Mix
    • 24 mL coating buffer
    • 80 μL primary antibody
  • Add 100 μL per well (96-wells plate)
  • Incubate ON

Preparing Sandwich

  • Wash coated plate 5x 200 μL PBS
  • Remove PBS
  • Add 200 μL BSA
  • Incubate 1h @ RT and remove BSA
    • Dilute samples as shown below for each 24-wells (dilution buffer (μL)/sample (μL))


24-wells (dilution buffer (μL)/sample (μL))
1 2 3 4 5 6
A 100/100 100/100 100/100 100/100 100/100 100/100
B 150/50 150/50 150/50 175/25 175/25 175/25
C 150/50 150/50 150/50 175/25 175/25 175/25
D 150/50 150/50 150/50 175/25 175/25 175/25


  • Wash of BSA with 200 μL Washing buffer 5x
  • Add 100 μL of diluted sample
  • Incubate ≥1h @ RT
  • Wash 5x 200 μL Washing buffer
  • Remove buffer
    • prepare biotinylated antibody
  • Add 100 μL Biotinylated antibody
  • Incubate 1h @ RT
  • Remove antibody
  • Wash 5x 200 μL Washing buffer
  • Add 100 μL streptavidin conjugated to HRP
  • Incubate 25 min. @ RT
  • Remove liquid
  • Wash 5x 200 μL Washing buffer
    • prepare TBM substrate
    • 1.2 μL H2O2 (30%)
    • 400 μL TBM stock solution
    • 24 mL substrate buffer
  • Add 100 μL substrate
  • Incubate 30 min. @ RT
  • Stop reaction, add 100 μL stopping solution
    • It will turn yellow
  • Measure absorbance @ 450 nm
    • Check duplo standard curve
    • Check if values fall within standard curve (preferred)

Notes

  • Of the 96-wells plate well F1 contain a Polystyrene fragment

Results

  • Standard curves were accurate (R square 1>0.99)
  • Negative controls showed hardly any IL-8 secretion into the medium (see figures below)


Image 180220101: The average IL-8 secretion of donor 9 corrected for cell viability. Error bars represent standard deviation. CTR: control, CSE: Cigarette smoke extract, 8-p: 8-pcpt-2'-o-me-camp, Bnz:6-Benz-cAMP.

Image 180220102: The average IL-8 secretion of donor 12 corrected for cell viability. Error bars represent standard deviation. CTR: control, CSE: Cigarette smoke extract, 8-p: 8-pcpt-2'-o-me-camp, Bnz:6-Benz-cAMP.

  • Donor 9 showed twice as low IL-8 concentrations (see figures

Conclusion

  • It appears that HT31P affects the cells viability negatively.
  • When comparing the effect of CSE without (HT31P) and with (HT31) PKA/AKAP interaction inhibition, it seems that when AKAP/PKA association is inhibited it decreases CSE induced IL-8 release.
    • PKA/AKAP interaction is required for CSE induced IL-8 secretion.
  • When inducing Epac no effect is seen when comparing the HT31 situation, however slight decrease of IL-8 production is seen when HT31P control situation receives Epac stimulation.
    • When Epac can compete with PKA for the present cAMP it inhibits the increased IL-8 secretion.
    • Epac does not have an influence when PKA can not have its effect
  • Increased PKA activity induces inhibition of IL-8 secretion even without AKAP association
    • It might be that PKA is activated prior to AKAP association, removing its necessity


  • PKA/AKAP induces IL-8 secretion, however an excess of active PKA with/without AKAP association lowers IL-8 secretion
    • Ht31 does not prevent the activation of PKA, only its localization close to cAMP sources and PKA effectors
  • PKA is the more important effector of cAMP compared to Epac

Related entries

Run 1: Ht31/Ht31P D9/D12

Attachment

<html> <a href="http://openwetware.org/wiki/Image:HTERT_Donor_12_ht31_160310.xls"> 

  <img src="http://openwetware.org/images/f/f8/Owwnotebook_icon.png" alt="" width="50" height="50">

</a> </html> Excel hTERT D9
<html> <a href="http://openwetware.org/wiki/Image:HTERT_Donor_12_ht31_160310.xls"> 

  <img src="http://openwetware.org/images/f/f8/Owwnotebook_icon.png" alt="" width="50" height="50">

</a> </html> Excel hTERT D12


Retrieved from "https://openwetware.org/mediawiki/index.php?title=User:Wilfred_J._Poppinga/Notebook/cAMP_compartmentalization/2010/02/18&oldid=402184"